Harvard Bioscience (HBIO) Non-Current Assets (2010 - 2026)

Harvard Bioscience (HBIO) has reported Non-Current Assets for 17 consecutive years, with $29.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 15.09% year-over-year to $29.8 million in Q2 2026; TTM through Jun 2026 was $126.3 million, a 46.48% decrease from a year earlier, with the FY2025 full-year figure at $31.8 million, down 60.94% from the prior year.
• Non-Current Assets was $29.8 million for Q2 2026 at Harvard Bioscience, down from $30.5 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $98.8 million in Q2 2022 and troughed at $29.8 million in Q2 2026.
• A 5-year average of $71.0 million and a median of $84.7 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets slipped 1.63% in 2022 and sank 60.94% in 2025, its largest moves.
• Over 5 years, Non-Current Assets stood at $94.2 million in 2022, then dropped by 6.27% to $88.3 million in 2023, then dropped by 7.7% to $81.5 million in 2024, then slumped by 60.94% to $31.8 million in 2025, then declined by 6.35% to $29.8 million in 2026.
• The last three Non-Current Assets figures came in at $29.8 million (Q2 2026), $30.5 million (Q1 2026), and $31.8 million (Q4 2025), per Business Quant data.